rac-2-bromo-N-(1-methyl-3-phenyl-piperidin-3-yl)-4-trifluoromethyl-benzamide | 1236303-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: rac-2-bromo-N-(1-methyl-3-phenyl-piperidin-3-yl)-4-trifluoromethyl-benzamide
• 英文别名: 2-bromo-N-(1-methyl-3-phenylpiperidin-3-yl)-4-(trifluoromethyl)benzamide
• CAS: 1236303-54-0
• 化学式: C₂₀H₂₀BrF₃N₂O
• 分子量: 441.291
• InChiKey: QTLISNUANNWWKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-Cbz-3-哌啶酮 在 lithium aluminium tetrahydride 、 sodium azide 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 三氟乙酸 为溶剂， 反应 23.75h， 生成 rac-2-bromo-N-(1-methyl-3-phenyl-piperidin-3-yl)-4-trifluoromethyl-benzamide
  参考文献：
  名称：

  3-Amido-3-aryl-piperidines：一类新型的有效、选择性和口服活性 GlyT1 抑制剂

  摘要：

  3-Amido-3-aryl-piperidines 被发现是一种新型结构的 GlyT1 抑制剂。所开发的构效关系导致鉴定出对 GlyT2 异构体表现出优异选择性、类药物特性和口服给药后体内活性的高效化合物。

  DOI：

  10.1021/ml500005m

文献信息

• PIPERIDINE DERIVATIVES
  申请人：Kolczewski Sabine

  公开号：US20100197715A1

  公开（公告）日：2010-08-05

  The present invention relates to a compound of formula I wherein R 1 , R 2 , and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. These compounds and their pharmaceutical compositions are useful in the treatment of neurological and neuropsychiatric disorders.

  本发明涉及式I的化合物，其中R1、R2和Ar定义如本文中所述，或涉及一种药物可接受的酸性加成盐，或涉及其相应的对映体和/或光学异构体。这些化合物及其药物组合物可用于治疗神经和神经精神障碍。
• AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2391603B1

  公开（公告）日：2014-01-08
• US9067911B2
  申请人：——

  公开号：US9067911B2

  公开（公告）日：2015-06-30
• [EN] AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS<br/>[FR] PIPÉRIDINES SUBSTITUÉS PAR AROYLAMINO ET HÉTÉROAROYLAMINO COMME INHIBITEURS DE GLYT-1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010086251A1

  公开（公告）日：2010-08-05

  The present invention relates to a compound of general formula (I) wherein R1 is hydrogen, lower alkyl, CD3, -(CH2)n-CHO, -(CH2)n-O-lower alkyl, -(CH2)n-OH, -(CH2)n-cycloalkyl or is heterocycloalkyl; R2 is hydrogen, halogen, hydroxy, lower alkyl, di-lower alkyl, -OCH2-O-lower alkyl, or lower alkoxy; or the piperidin ring form together with R2 a spiro ring, selected from 4-aza-spiro[2.5]oct-6-yl; Ar is aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, lower alkoxy, S-lower alkyl, heteroaryl, heterocycloalkyl, or by phenyl optionally substituted by R', and R' is halogen, lower alkyl, lower alkoxy or lower alkoxy substituted by halogen, or is heteroaryl; R is lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein aryl and heteroaryl are optionally substituted by one or two R'; n is 0, 1 2 or 3; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. Furthermore, the present invention relates to pharmaceutical compositions containing the compounds of formula I and to their use in the treatment of neurological and neuropsychiatric disorders.